Recent changes in the landscape of combination RAS blockade (Q37629835)

21 August 2017

1 reference

title

Recent changes in the landscape of combination RAS blockade (English)

1 reference

21 August 2017

Benjamin J Epstein

1

1 reference

PubMed ID

19900020

21 August 2017

Steven M Smith

series ordinal

2

1 reference

PubMed ID

19900020

21 August 2017

Rushab Choksi

series ordinal

3

1 reference

21 August 2017

1 November 2009

1 reference

Expert Review of Cardiovascular Therapy

21 August 2017

1 reference

21 August 2017

7

1 reference

21 August 2017

11

1 reference

21 August 2017

1373-1384

1 reference

Renin-angiotensin system and cardiovascular risk

21 August 2017

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.127

Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.127

Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.127

The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.127

Telmisartan, ramipril, or both in patients at high risk for vascular events

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.127

Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.127

Blocking the renin-angiotensin system: dual- versus mono-therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.127

Managing cardiovascular and renal risk: the potential of direct renin inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.127

Angiotensin receptor blockers versus ACE inhibitors: prevention of death and myocardial infarction in high-risk populations

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.127

Renin inhibition in hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.127

Plasma bradykinin in angio-oedema.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.127

Therapeutic implications of escape from angiotensin-converting enzyme inhibition in patients with chronic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.127

Long-term effects of ramipril on cardiovascular events and on diabetes: results of the HOPE study extension

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.127

Follow-up study of patients randomly allocated ramipril or placebo for heart failure after acute myocardial infarction: AIRE Extension (AIREX) Study. Acute Infarction Ramipril Efficacy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.127

Antihypertensive efficacy of the oral direct renin inhibitor aliskiren as add-on therapy in patients not responding to amlodipine monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.127

RAS blockade with ARB and ACE inhibitors: current perspective on rationale and patient selection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.127

The angiotensin II type 2 receptor: what is its clinical significance?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.127

The two fACEs of the tissue renin-angiotensin systems: implication in cardiovascular diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.127

Prorenin and (pro)renin receptor: a review of available data from in vitro studies and experimental models in rodents

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.127

Aliskiren fails to lower blood pressure in patients who have either low PRA levels or whose PRA falls insufficiently or reactively rises

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.127

The renin rise with aliskiren: it's simply stoichiometry

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.127

Effects of aliskiren on blood pressure, albuminuria, and (pro)renin receptor expression in diabetic TG(mRen-2)27 rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.127

Systematic review of combined angiotensin-converting enzyme inhibition and angiotensin receptor blockade in hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.127

Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.127

Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.127

Efficacy and safety of the direct renin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.127

Effect of the direct Renin inhibitor aliskiren, the Angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.127

Reductions in albuminuria and in electrocardiographic left ventricular hypertrophy independently improve prognosis in hypertension: the LIFE study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.127

A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.127

Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.127

Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.127

Combination of isosorbide dinitrate and hydralazine in blacks with heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.127

The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.127

2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.127

Adverse effects of combination angiotensin II receptor blockers plus angiotensin-converting enzyme inhibitors for left ventricular dysfunction: a quantitative review of data from randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.127

Preventing microalbuminuria in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.127

Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.127

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.127

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.127

Aliskiren combined with losartan in type 2 diabetes and nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.127

Predictors of cardiovascular events in patients with type 2 diabetic nephropathy and hypertension: a case for albuminuria

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.127

Losartan and other angiotensin II antagonists for nephropathy in type 2 diabetes mellitus: a review of the clinical trial evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.127

Management of glomerular proteinuria: a commentary

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.127

Mechanisms of progression and regression of renal lesions of chronic nephropathies and diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.127

Review: renal protection by inhibition of the renin-angiotensin-aldosterone system

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.127

Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.127

Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.127

Combination Therapy Versus Monotherapy in Reducing Blood Pressure: Meta-analysis on 11,000 Participants from 42 Trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.127

21 January 2018

Identifiers

DOI

10.1586/ERC.09.127

1 reference

21 August 2017

1 reference

PubMed ID

19900020